GLP-1 Superciclo — $168B 2035, CAGR 22.4%, 890M Población Elegible
Elaborado por el sistema de análisis del Cerebro (IA), con fuentes citadas · Revisado el 3 de septiembre de 2026 · Cómo trabajamos · Correcciones
Definición: Clase de fármacos (agonistas receptor GLP-1) que trasciende diabetes/obesidad para reescribir economía cardiovascular, dispositivos médicos, retail alimentario y manufactura farmacéutica simultáneamente. Superciclo confirmado: no es una droga, es un healthcare system stress test.
---
Magnitud del Superciclo (Emergen Research Q1 2026)
| Métrica | Valor | Significado |
|---|---|---|
| Market size 2025 | $26.8B | Base real |
| Market size 2035 | $168B | Proyección estructural |
| Revenue CAGR 2025-35 | 22.4% | Superciclo confirmado |
| Población elegible | 890M adultos obesos | Global, no solo US/EU |
| Ecosystem value 2025-35 | $1.2T cumulative | Healthcare system impact |
| US users 2025 | ~10M | 6M 2024, 5M 2023 |
| US users 2030 | 25-30M | JPMorgan forecast |
| Global users 2030 | ~100M | Extrapolación |
---
Duopolio actual: Lilly vs Novo (Q4 2025)
| Empresa | Portfolio | Revenue | Growth | Posición |
|---|---|---|---|---|
| Eli Lilly | Mounjaro (diabetes), Zepbound (obesidad) | $19.3B Q4 2025 | +43% YoY | Líder aceleración |
| Foundayo (oral orforglipron) | FDA approved Apr 2026 | Triple agonista pipeline | ||
| Retatrutide (triple agonist) | Phase 3 | 2030+ | ||
| Novo Nordisk | Ozempic (diabetes), Wegovy (obesidad) | DKK 201.8B ($29.3B) 2024 | +26% CER 2024 | Líder estable |
| Rybelsus (oral semaglutide) | DKK 65.1B ($9.5B) 2024 | +57% CER | Oral advantage | |
| CagriSema (semaglutide+cagrilintide) | Phase 3 | 2027+ |
Desacoplamiento 2025: Lilly tirzepatide Q4 $11.6B vs Novo Ozempic DKK 31.8B (+1% CER) → Lilly lidera crecimiento.
---
Catalizadores estructurales 2026-2030
1. Oral GLP-1s: Game changer — manufacturabilidad vs inyectables
| Producto | Tipo | Estado | Impacto |
|---|---|---|---|
| Foundayo (Lilly) | Oral small molecule | FDA approved Apr 2026 | No fill-finish constraint |
| Orforglipron | 27.3 lb weight loss (Phase 3) | Daily dosing, no food/water | |
| Wegovy oral (Novo) | Oral semaglutide | FDA approved Dec 2025 | 16.6% weight loss at 64 weeks |
| Rybelsus oral | Existing | Daily, but requires fasting | |
| Amycretin (Novo) | GLP-1/amylin oral | Phase 1 | 13% weight loss in 12 weeks |
Manufacturabilidad: Oral = tablet lines vs injectables = cold chain, sterile fill-finish → escala masiva.
2. Manufacturing capacity: $50B+ capex — API bottleneck
| Empresa | Investment | Timeline | Focus |
|---|---|---|---|
| Eli Lilly | $27B (2025) | 2027-2030 | API + injectables + oral |
| Lebanon, IN | 2027 | Largest API site US history | |
| Goochland, VA | 2028 | Integrated API + drug-product | |
| Germany (Lonza) | 2028 | GLP-1 API facility | |
| Novo Nordisk | $9B (2025) | 2027-2029 | Fill-finish + API |
| Clayton, NC #2 | 2027-2029 | 1.4M sq ft, 1,000 jobs | |
| Athlone, Ireland | 2027-2028 | Oral GLP-1 capacity | |
| Kalundborg, Denmark | 2024 | API expansion |
Bottleneck actual: Fill-finish capacity → 35% demand > supply through 2027 (Emergen Research).
3. Label expansions: Beyond obesidad → comorbidades
| Indicación | Empresa | Estado | Impacto |
|---|---|---|---|
| HFpEF (heart failure) | Novo semaglutide | FDA review Q1 2026 | 3.5M US patients |
| Sleep apnea | Lilly tirzepatide | Phase 3 | Sleep quality improvement |
| NASH (liver disease) | Boehringer survodutide | Phase 3 | Metabolic steatohepatitis |
| Kidney disease | Multiple | Phase 2-3 | Renal protection |
| Neurodegenerative | Multiple | Preclinical | Alzheimer's, Parkinson's |
Impacto: Cada nueva indicación duplica el mercado addressable.
4. Payer coverage: IRA pricing access inflection
| Payer Type | Coverage Status | Pricing Impact |
|---|---|---|
| Medicare Part D | Ozempic/Wegovy in Round 2 | $274/month vs $959 list (Jan 2027) |
| Tirzepatide not in Round 2 | Protected until 2029+ | |
| Commercial insurance | ~25% cover obesidad | Near-universal for diabetes |
| Medicaid | Limited coverage | Expansion ongoing |
| Self-pay | $349-$1,349/month | Cash market growing |
Timeline crítico: Jan 2027 IRA pricing takes effect → access expansion.
---
Pipeline: Next wave 2026-2030
Triple agonists (2027-2030)
- Retatrutide (Lilly): Triple GLP-1/GIP/glucagon → Phase 3 obesidad
- CagriSema (Novo): Semaglutide + cagrilintide → Phase 3
- Survodutide (Boehringer): Glucagon + GLP-1 → NASH + obesidad
Oral formulations (2026-2027)
- Foundayo (Lilly): Approved Apr 2026 → oral small molecule
- Wegovy oral (Novo): Approved Dec 2025 → oral semaglutide
- Amycretin (Novo): GLP-1 + amylin → Phase 1
Combination therapies (2028-2030)
- Multiple GLP-1 combinations → enhanced efficacy, tolerability
- Fixed-dose combinations → adherence improvement
Biosimilar inflection (2031-2033)
- Semaglutide biosimilars: FDA guidance Mar 2025 → first by 2033
- Price compression: 70-80% below brand → access expansion
---
Impacto sistema: $1.2T ecosystem value
Healthcare system impact
| Sector | Impact | Timeline |
|---|---|---|
| Cardiovascular procedures | Reduced events | 2027-2030 |
| Diabetes management | Lower HbA1c, complications | 2026+ |
| Kidney disease | Slowed progression | 2028+ |
| Healthcare costs | $30-55B annual reduction | 2030-2034 |
Food & beverage impact (JPMorgan 2026)
- US households with GLP-1 users: -12% snack food, -9% sugary beverages, +7% protein
- Industry revenue reduction: $30-55B by 2030-2034
- Consumer behavior: 21% fewer calories, 31% less grocery spending
Food industry response
- Nestlé: Dedicated GLP-1 nutrition platform (Oct 2024)
- Conagra: 40 SKUs reformulated for reduced portions + protein
- General Mills: Protein-focused product development
---
Jugadores principales — Posicionamiento 2026
| Empresa | Modelo | Posición | Thesis Status |
|---|---|---|---|
| Eli Lilly | GLP-1 platform (tirzepatide + orforglipron) | BUY | Triple agonist, oral advantage, IRA protection until 2029 |
| Novo Nordisk | GLP-1 legacy (semaglutide + oral) | WATCHLIST | Strong brand but IRA exposure 2027, CagriSema execution risk |
| Amgen | MariTide (once monthly dual action) | WATCHLIST | Long-acting formulation, obesity entry |
| Boehringer Ingelheim | Survodutide (glucagon + GLP-1) | WATCHLIST | NASH + obesity, metabolic focus |
| AstraZeneca | Partnership with CSPC China | WATCHLIST | China market access, innovation sourcing |
| Merck | Keytruda (oncology crossover) | WATCHLIST | Cardio-metabolic potential |
| Pfizer | Metsera acquisition (2025) | WATCHLIST | Obesity portfolio expansion |
| Sanofi | Multiple GLP-1 partnerships | WATCHLIST | Late entry, potential upside |
---
KPIs para valorar empresa GLP-1 (actualizado)
- Portfolio diversification: Multiple GLP-1 assets across routes/oral/injectable
- Manufacturing capacity: API vs fill-finish, geographic diversification
- Payer coverage: Commercial/Medicaid/Medicare penetration, IRA exposure timing
- Pipeline depth: Next-gen agonists, oral formulations, combination therapies
- Real-world evidence: Persistence rates, cardiovascular outcomes, system cost savings
- Global reach: US/EU/Japan/China market access, emerging market penetration
- Biosimilar strategy: Patent cliff timing, biosimilar pipeline development
- Manufacturing economics: Cost per dose, scale advantages, cold chain requirements
---
Banderas rojas sector (actualizado)
- IRA pricing compression: Semaglutide exposed Jan 2027 → $274/month vs $959 list
- Manufacturing overcapacity: Fill-finish capacity at risk if oral wins share faster
- Persistence rates: Current 30-35% → needs to stabilize >40% for system value
- Competition intensification: Multiple entrants → pricing pressure, differentiation challenge
- Oral adoption: Adherence challenges with daily dosing vs weekly injections
- Global access: Pricing in emerging markets, supply chain constraints
- Regulatory pathway: Biosimilar guidance established but execution uncertain
---
Las dos caras hoy (sep-2026)
Alcista:
- Superciclo confirmado: $168B 2035, CAGR 22.4%, 890M eligible population
- Lilly lidera crecimiento: Tirzepatide $11.6B Q4 2025, Foundayo oral advantage, IRA protection until 2029
- Oral GLP-1s: Foundayo approved Apr 2026, Wegovy oral Dec 2025 → manufacturabilidad revolution
- Manufacturing $50B+ capex: API + fill-finish expansion, supply constraint through 2027
- Ecosystem value $1.2T: Healthcare system impact, food industry transformation
- Cartera Carlos 0% farma = hueco diversificación factorial real (innovación defensiva, healthcare secular)
Bajista:
- IRA pricing compression: Novo semaglutide exposed Jan 2027 → $274/month vs $959 list
- Manufacturing risk: Fill-finish capacity at risk if oral wins share faster than expected
- Persistence rates: Current 30-35% → needs >40% for sustainable system value
- Competition wave: Multiple entrants → pricing pressure, differentiation challenge
- Valoraciones: Multiples exigentes para líderes vs historia farmacéutica
---
Ver también
— dato privado retirado —